The epigenome -the chemical modifications and packaging of the genome that can influence or indicate its activity -gives a molecular insight to cell-type specific activity. It can, therefore, reveal the pathophysiological mechanisms at work in disease. Detected changes can also represent physiological responses to adverse environmental exposures, thus enabling the epigenetic mark of DNA methylation to act as an epidemiological biomarker, even in surrogate tissue.
INTRODUCTION
Epigenetic factors include the chemical modifications of DNA and the proteins that the DNA wraps around, which influence or may indicate the activity of genes. Deciphering these marks can be a powerful method to understand the specialised functioning of a cell and organs (1) . Furthermore, they may inform how molecular mechanisms are impeded in disease or due to adverse environments.
Obesity rates have increased at such a magnitude that this clearly points towards non-genetic, or environmental factors, as the significant driver.
Identified genetic susceptibilities are also modulated by these external influences (2, 3). This has led to considerable interest in the study of the epigenome with the potential to quantify gene activity changes due to this environment, as well as the possibility of gaining molecular understanding of the pathophysiological consequences of the obese state. Crucial biological understanding of obesity and its consequences are still lacking (4, 5) and would help focus vital preventative measures to counter obesity's substantial morbidity and mortality risk (6) .
THE EPIGENOME
DNA is packaged at the strand level by wrapping around Histone proteins that comprise of 8 subunits, two of each of Histone 2A, 2B, 3 and 4.
The histone proteins possess tails that can be post-translationally modified, including the addition of methyl or acetyl groups to Lysine (K) molecules on histone 3 (H3). These additions can be related to active or repressed regions depending upon which K is modified. Amino acid deviation in the protein structure of these histone molecules, termed Histone Variants, also modify activity and can as well be associated with disease processes (7) .
Chemical modifications of DNA itself include the most common, stable and well-studied, DNA methylation, or the addition of a methyl group onto the 5' carbon of cytosine. This robust chemical mark is due to the strong covalent carbon-to-carbon bond that connects cytosine to the methyl group. In differentiated cells this occurs in the DNA sequence predominately within the context of a CpG dinucleotide, that is where Guanine follows Cytosine in the 5' to 3' direction on one DNA strand. It acts canonically as a repressive mechanism within gene promoters. However, additional DNA modifications occur, and these are in fact progressive oxidative products of the active DNA demethylation process, driven by the TET enzymes, leading firstly to hydroxymethylcytosine (5hmC), formylcytosine (5fC) and then carboxycytosine (5caC). This final product is then recognised by the baseexcision pathway to enable return to an unmodified cytosine (8) . These less common modifications may also in themselves possess active roles, with 5hmC implicated functionally within enhancers (9) .
High-throughput analysis of the epigenome is focused now on DNA methylation, particularly because of its stability in extracted DNA in comparison to other epigenetic marks, such as histone modifications.
However, due to its biological plasticity it is an attractive biomarker with strong potential clinical utility (10).
CONSIDERATIONS IN THE ANALYSIS OF THE EPIGENOME
To powerfully examine the epigenome, especially in a human population setting (11) , it is necessary to be clear how this mechanism contrasts from the genome. This understanding impacts significantly on design, analysis and interpretation. The differences can be broadly encapsulated in three principles: i) cell-type specificity ii) changeability and iii) sequence interactive (or positional) effects.
Firstly, as its function dictates, the epigenome is tissue or cell-type specific. Therefore, we wish, if at all possible, to be examining the cell-type(s) that are most relevant to the pathophysiology of the disease. We can only interpret any associated findings in tissue that is not the primary site of action as a surrogate measure for markers of exposure, which may also act on the organ of disease, or downstream physiological changes due to these exposures or disease outcomes. In the analysis of obesity this is not straightforward, as the intrinsic genetic predisposition is governed largely within the brain (12) , with central control for energy balance directed by specific hypothalamic neurons, particularly within the arcuate nucleus (13) .
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Thus, these cells are inaccessible except in post-mortem samples. Adipose tissue is also an obvious focal interest for the dissection of obesity, with the physical and functional changes that occur to it and its role as an endocrine organ (5).
Secondly, the epigenome is changeable over time. This is most dramatic during development, where two rounds of epigenomic reprogramming occur, firstly in gamete formation and then secondly postfertilisation. These are both characterised by global DNA demethylation (14) .
However, the epigenome is not static from this time-point. It is seen to suffer from 'epigenetic drift' with age, whereby hypomethylated regions gain and hypermethylated regions lose methylation over time stochastically throughout the genome (15) . This process is proposed to be involved in age-related deterioration in function, and the concurrent increased risk of chronic diseases, such as obesity-related conditions. Though, on top of this are specific directional ageing changes that can be identified at defined functional loci across the genome (16, 17) .
Thirdly, positional effects driven through sequence variation will be reflected in the measured epigenome. These can be direct, in cis, or trans, and can bedevil the analysis in human population samples, particularly across diverse ancestries (11) (Figure 1 ). Direct effects with respect to DNA methylation can be due to genetic polymorphism at the CpG dinucleotide itself. In fact, almost ~⅓ of SNPs occur at CpG locations, because of the hypermutability of methylated cytosines, and this contributes considerably to allelic variation in the DNA methylome (18, 19) .
The observed epigenetic state may represent the activity or repression of local cis-regulatory elements (CREs) (usually 100-1000 bp in length) (20) .
Genetic variability within these regions can led to fixed obligatory epigenetic positions or facilitate epigenetic variation (21) . Genetic effects on the methylome via transcription factors (TFs) has been known for decades, such as the role of SP1 within CpG islands (22) . Motif changes in this and other Methylation Determining Regions (MDR), such as those for CTCF and RFX, give rise directly to methylation variation in CpG dense regions (23) . TFs binding to transcription factor binding sites (TFBS) can also drive down DNA methylation (24) at distal regulatory regions and thus genetic variation in these binding sites will also be influential. Some TFs are explicitly sensitive to DNA methylation (25) and some, in fact, require it in order to bind (26) . Also SNPs affecting the expression of trans factors will impact on the epigenetic state within their distal TFBS or CRE regions (27). Genetic influence on the epigenome is in fact so strong that it can be observed in enhancer variation in only 19 individuals of diverse ancestry (28) .
Nearby positional effects such as polymorphic insertions of often heavily methylated retrotransposons will influence the local region (29) . The density of CpGs also has a direct relationship with the DNA methylome (30), so CpG-SNPs (SNPs creating or abrogating a CpG dinucleotide (18, 31) ) as well as affecting available methyl-C containing motifs, can impact on the rate of change of CpG density slopes. The influence of SNPs as mQTL (methylation QTL) (32), can capture impact upon cis or trans factors, the DNA methylation machinery, or haplotypic effects, such as regional density or proximity factors. Genetically-associated correlated CpGs can be observed to cluster, which have been termed 'GeMes' (33). Finally, the epigenome is a coordinated mechanism so the epigenetic layers should fit logically together, such that a DNA hypermethylated promoter should show lack of co-locating activating chromatin marks and vice versa (34).
CONFOUNDING ISSUES
All the above effects, tissue-specificity, changeability, and sequence interaction, can therefore confound or misattribute action or effect in epigenomic studies. To mitigate against these, rigorous study designs have been proposed and employed. However, due to practical, technical and cost considerations, it is often not possible perform the ideal study, but to compromise, acknowledge and work within these limitations (35, 36).
Isolating disease-relevant tissue cell-types for analysis is an obvious first starting point. However, many large epidemiological studies have DNA derived from peripheral blood available, with the positive that these are often sizeable numbers and possess deep phenotyping. Whilst these are the practicalities, an argument may be made that peripheral blood is of interest physiologically in obesity due to known inflammatory related changes (37) or Page 6 of 42 Obesity for detection of passive exposure biomarkers. Furthermore, the potential clinical utility of findings in blood is significant due to its comparative ease of access compared to fat-tissue biopsy. However, these DNA methylation differences will be unlikely to correlate with other target tissues. Postmortem samples or tissue biopsies are required to gain further insights into underlying mechanisms.
The additional factor regarding peripheral blood analysis is that it comprises of the various leukocyte cell-types and as such represents a metaepigenome of these subsets contained (38). This mixture needs to be quantified and even in normal conditions these vary between individuals due to many factors including sex and genetic background. Thus, DNA methylation profiling in blood will strongly identify signals driven by sub-cell composition changes due to the disease state or immune responses associated with it. Whilst isolation of the most disease relevant cell-type is preferable (39), deconvolution algorithms have been devised using Differentially Methylated Positions (DMPs) that estimate leukocyte cell-type proportions (40). In fact, due to the cell-type specificity of epigenomes, once accurately delineated, this deconvolution is set to become one of the most powerful epigenomic tools. The mapping of these cell and tissue types is beginning through efforts such as the Epigenomics Roadmap (41), Blueprint clearly, as mentioned, in peripheral blood, with responses to acute infection or even chronic low-grade inflammation (45). Other significant proportional changes occur due to ageing, with a skew towards a greater myeloid cell fraction in blood (46), but also a reduced ratio of neurons to glia in the brain (47) . However, in many studies the phenotype of interest may alter the proportional composition of the cell types within the analysed target tissue (48) . In fact, in some cases, correction for cell-type may impede the identification of cell-type specific modifications (49) .
Finally, the influence of genetic factors on the epigenome is strong.
Therefore considerable power comes from longitudinal studies (35), or monozygotic (MZ) or identical twin discordant analyses, to remove these significant influences (50, 51) . In high-throughput DNA methylation array analysis the influence of genetic effects can be driven by SNPs at the investigated CpGs themselves, under the probes, or nearby ( Figure 1 ). Drastic effects led to discrete genotypic grouping or "gap signals", with 11,007 seen in a recent Illumina Infinium Human Methylation450 bead chip (450k array) analysis (52) . Previous 450k array analysis has found population genetic variation attributable in 66,877 probes (13.8%) (53). Chen et al. observed recently this strong genetic influence in a study of genetic drivers of epigenetic variation in human immune cells and it was noted to be a concern for EWAS interpretation (54) . More complex haplotyptic effects may also exist, with strong consequences captured by "gap signals", though more subtle outcomes will converge. Although how these genetic influences cannot only confound studies, but also may facilitate functional variation, should also be borne in mind. CpG-SNPs are proposed to play a significant facilitative epigenetic role and these effects were recently seen be to enriched within GWAS regions in a number of studies, including Type 2 Diabetes (55-57)
CELL-TYPE SPECIFIC SIGNALS IN PERIPHERAL BLOOD
Dissecting the strong DNA methylation signals that can be identified with tobacco smoking in peripheral blood starts to reveal the biological intricacies of epigenetic changes in this heterogeneous tissue. Understanding these robust results is very useful in interpreting what may be possible in DNA methylation studies of obesity and other diseases. There are distinct results dependent upon which cellular subset is examined (58) . The strongest tobacco-associated signal in the gene AHRR appears so conspicuously as the epigenetic change occurs specifically within granulocytes and monocytes and is then amplified by the fact that smoking itself increases the proportion of granulocytes in peripheral blood. By contrast tobacco has little impact on AHRR T cell DNA methylation. In comparison, lymphoid-specific inflammatory changes, such as those seen in GPR15, where DNA methylation changes are only seen in T and B cells (58, 59) . Biologically these changes are likely inflammatory responses driven by smoking injured tissues. On the myeloid side, monocyte to macrophage differentiation is influenced, as well as a proposed carbon monoxide environmental selection on bone marrow progenitor cells (58) . Thus, the identification of these subtype specific signals enable novel hypotheses and mechanism to be proposed and explored.
OBESITY-INDUCED CHANGES IN FAT AND BLOOD
Fat tissue is not a homogenous organ. The adipocytes of subcutaneous fat are mostly white adipocytes, due to triglyceride storage, which are leptin and adipokine-secreting. Additionally, there are small but discernable levels of brown and beige fat (5) . The role of brown fat in humans has gained significant interest due to its energy-dissipation properties and fat burning actions via uncoupling protein 1-containing mitochondria. Stimulation by the sympathetic nervous system after cold exposure leads to heat production.
Beige, or brown-to-white thermogenic adipocytes, have a progenitor cell origin and conversion can be induced by cold temperatures, exercise and endocrine factors (5).
In obesity, adipose tissue becomes a large immunologically active endocrine organ (60) . Infiltration by macrophages and other inflammatory immune cells occurs, partly due to obesity-related apoptosis of adipose cells (60) . This leads to chronic adipose tissue inflammation (61) with the secreted proinflammatory cytokines contributing to the insulin resistant state that arises (62) . Visceral fat deposits, including the omentum and mesenteric fat, are more detrimental than subcutaneous (63) and are associated with many of the systematic metabolic consequences of obesity (5).
Obesity induces changes in innate immune cells, but also increases in CD4 + and CD8 + T cells and reduces tolerance-promoting regulatory B cells as well as inducing abnormal B cell function (64) . There is a proposed role in obesity of lymphoblast-derived Natural Killer (NK) cells, which are shown to be significant regulators of macrophage polarization and insulin resistance (65) , and their methylome is remodelled in conversion from naive to activated cells (66) . Chronic low-grade inflammation is associated with obesity, and specific DNA methylation changes are observed, due to this state, assessed via Creactive protein levels (CRP), within peripheral blood (45).
ANALYSIS OF THE EPIGENOME IN OBESITY
Studies of obesity epigenetics up to the beginning of this decade were predominately either targeted candidate genes or total measures of the epigenome, such as global DNA methylation (67) . The later can be useful in gross abnormalities, such as cancer, when significant hypomethylation is strong enough to drive global variation. Though it is far less useful in more nuanced phenotypes and has not lead to consistent findings (68) . With the former, as was the experience in complex trait genetics, the study of candidate genes has not been particularly fruitful, with weak and again inconsistent effects. In the exploration of imprinting genes or those involved in metabolism, few (if any) have been supported by subsequent genome-wide, more powered and confounding-aware studies (68) . Many early studies therefore need reassessing in the light of current findings and knowledge.
All DNA methylation studies prior to at least 2012 are likely to have not taken the confounding effects of cell-type proportions into account. Furthermore, many of these studies are in small numbers, with added potential issues due to genetic heterogeneity. Whilst stronger effect size epigenetic associations can be found for phenotypic traits or complex diseases than genetic associations (69), lack of subsequent replication point to their weakness (68) .
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EPIGENOME-WIDE ASSOCIATION STUDIES FOR OBESITY (BMI) IN PERIPHERAL BLOOD
In 2014 Dick et al. published one of the first large Epigenome-wide Association Study (EWAS) for BMI using the 450k array (70) . This was performed in whole blood derived DNA in European ancestry individuals. The initial discovery set was 479 individuals, followed by two rounds of replication, firstly in 339 and then secondly in 1,789 samples. The discovery set identified 5 CpGs across 3 genetic loci associated with BMI. Three CpGs replicated and these all resided in the first intron of HIF3A, the Hypoxia Inducible Factor 3 Alpha Subunit gene, involved in regulating hypoxia-inducible gene expression (cg22891070, cg27146050, and cg16672562). Potential lymphocyte cell-type effects on cg22891070 were tested for, after the initial analysis. Whilst a small association with leukocyte number was seen, adjustment for subtypes did not substantially reduce the BMI association.
Then to investigate HIF3A across different tissues, DNA from adipose tissue (n=635) and skin (n=395), was assessed, with significant methylation changes identified in adipose only. One driver of this may be the high level of inflammatory blood cell invasion into adipose tissue. Genetic effects were explored and 2 SNPs (rs8102595 & rs3826795) were both independently associated with cg22891070's DNA methylation state in all datasets, although were not themselves significantly associated with BMI.
As well as being replicated in a number of studies (71) (72) (73) , including in adipose tissue (74) , this result was also explored for causality in the ALSPAC cohort from Bristol, U.K. (75) . Genetic and multiple time point DNA methylation data was available in 1,000 mother-offspring pairs. The DNA methylation changes were proposed to be secondary to differences in BMI, through examination of the temporal relationship of changes in sequential data, not causal, which was also supported by Mendelian Randomisation (MR) analysis.
In further analysis by Main et al. a relatively high level of familiarity (h 2 51-64%) for HIF3A DNA methylation in blood was observed (76), in fact a similar level to obesity itself. Epidemiological evidence has also pointed at vitamin B2 and B12 levels influencing HIF3A epigenetic levels (73).
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Another BMI EWAS analysis with the 450k array in peripheral blood DNA was performed in 2,097 African American adults in the Atherosclerosis Risk in Communities (ARIC) study (72 A comparison of the results from these three recent large EWAS studies (72, 77, 78 ) identified ten CpGs that were robust and replicated within each as well as being common to all (See Table 1 ). These ten CpGs are located in ten unique genes, predominately within intragenic intronic loci and in almost half within CpG island shores. They also are generally supported in other BMI-related studies (70, (82) (83) (84) (85) . Gene ontology enrichment analysis via GREAT for these ten CpGs (compared with the 450k array probes as background) identified nominal significance of biological processes, such as regulation of cholesterol and lipids, human phenotypes including hyperlipidemia, and diseases of the hepatobilary system (Supplementary Table S1 ).
In fact, many of these same CpGs are associated with lipid-related traits from specific EWAS's performed for these measures, assumedly due to their relationship to the development of adiposity or downstream-induced epigenetic changes from BMI-associated altered blood lipid profiles. A study of post gastric bypass DNA methylation variation in adipose tissue identified changes within genes associated with obesity by pre-and post-surgery weight-loss analysis (94) . Both omental and subcutaneous adipose tissue were compared and these give further insight to the dramatic physiological changes that occur with the rapid post-operative weight loss.
EWAS ANALYSIS IN ADIPOSE TISSUE
OBESITY AND AGEING ASSOCIATED CHANGES
Horvath et al. observed that obesity accelerates the detected epigenetic ageing of the liver when assessed by the Horvath 'Epigenetic Clock', but interestingly not in the other tissue types tested, including blood, adipose tissue, or muscle (95) . Obesity-related nonalcoholic fatty liver disease did not drive these hepatic changes. Although, it was postulated to be associated with obesity-driven liver comorbidities, including insulin resistance and hepatocellular carcinoma. The lack of changes in other tissues was hypothesized as due to liver-specific oxidative stress and also perhaps the suboptimal measure of obesity via BMI.
A study by Simpkin et al. identified that an accelerated epigenetic age measure at birth is also associated with a more rapid increase in BMI in childhood (96) . Furthermore, obesity is proposed to contribute to the 'exposome' that influences epigenetic ageing, with increased BMI from young adulthood to middle age contributing to a greater age acceleration (97) . In an analysis integrating blood derived ageing-related differentially 
DEVELOPMENTAL AND IN UTERO INFLUENCES
Critical windows may exist for environmental or intrauterine factors to impact on the epigenome, as it being defined, during early development (98) . These early changes are proposed to have the ability to act as 'metastable epialleles' that then propagate through the all germ layers to effect all cell types (99) . Although evidence for a role in DNA methylation in this process in human is not strong, the possibility for some repetitive elements such as SVAs (SINE-VNTR-Alu) to escape the global demethylation, subsequent reprogramming, and then be vulnerable to environmental influence cannot be excluded at this stage (14) .
Epidemiological data has proposed that in utero exposure to under- The genetic component of these maternal adiposity epidemiological observations has been recently dissected through large-scale GWAS and was seen to be a significant, but not complete, contributor (104) . Furthermore, Richmond et al. performed a direct MR analysis, using a weighted genetic score from variants for BMI, for maternal obesity influences in children from ages 7-18 years. In over 2,000 samples in both discovery and replication sets, they found little support for a strong causal intrauterine effect of increasing maternal BMI with increased childhood adiposity (105) . The complexity of this MR analysis in this scenario was recently discussed by Lawlor et al. (106) .
LIMITATIONS AND FUTURE DIRECTIONS
Current large-scale high-throughput analysis is limited to DNA methylation array-based techniques, commonly the 450k array and the more recent 850k array. These provide only a partial story with regards to the DNA methylome as ~28 million CpGs reside within the genome, as well as the additional potential for non-CG changes. An obvious area of underexploration by this approach is repetitive elements, which are proposed to conceal significant functionality, such as the strong overlap of chromatin enhancer evidence within LTR repeat class member LTR12C (107) . Examples also include a potential epigenetic role for an Alu repetitive element in POMC in childhood obesity (108) .
Furthermore, co-ordinated variation across a functional region, such as an enhancer, by the delineation of a significant DMR can increase statistical and biological confidence of the result (109) . However, sparse array data are not the most powerful for robust DMR calling (110) . Enrichment for disease ontology based results is stronger using sequencing-derived DMRs rather than isolated DMPs (58) . Thus, larger and more in depth sequencing-focused analyses could identify further novel findings. 
CONCLUSION
Epigenomic analysis is a significant tool in the hunt to improve risk prediction, as well as prognosis, beyond the rudimentary measure of BMI for obesity-related diseases. By observing at a molecular level the biologically perturbed mechanisms associated with this disorder, we may understand more precisely, for instance, the significant pathogenic influence of visceral fat. On the epidemiological side, whilst population-based strategies have borne the greatest improvements in human health in the past, there is now evidence that this may not be the case for obesity (120) . More focused policies may be required due to its widening distribution over time. bias in DNA methylation EWAS (69) . This trajectory will enable us to more accurately define the epigenome and interpret these findings. Increased high-throughput access to distal regulatory regions via the 850k array, larger sample-sized sequencing-based DNA methylome studies, and the analysis of additional modifications, including population chromatin data, will drive forward this progress. Also, the potential of 3rd generation sequencing to directly assess DNA modifications will be a significant step for epigenomics (126) . We will be able to more accurately define currently abstractly lumped together 'environmental' change, by more precisely excluding or integrating genetic effects, as well as defining cell-type specific and cell proportion changes, including increasingly rare cell-types. With this will come improved biological interpretation and understanding of critical pathological changes within defined cell-type(s), and genetic pathways. This knowledge will hopefully help reduce the chronic burden of obesity worldwide. 
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